Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $24.88 and last traded at $25.16, with a volume of 198268 shares. The stock had previously closed at $25.39.
Analyst Ratings Changes
Several research firms recently weighed in on CLDX. Wolfe Research lowered shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They set a "neutral" rating and a $45.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Monday, October 28th. Finally, Citigroup initiated coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $70.00 price objective on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $62.25.
Check Out Our Latest Stock Report on Celldex Therapeutics
Celldex Therapeutics Stock Down 0.5 %
The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -9.27 and a beta of 1.60. The stock's fifty day moving average is $34.64 and its two-hundred day moving average is $36.12.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The business had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. As a group, analysts anticipate that Celldex Therapeutics, Inc. will post -2.5 EPS for the current year.
Institutional Investors Weigh In On Celldex Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Celldex Therapeutics by 19.8% during the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company's stock worth $153,215,000 after purchasing an additional 604,251 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company's stock worth $129,571,000 after acquiring an additional 2,664,915 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of Celldex Therapeutics by 15.7% in the first quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company's stock worth $117,374,000 after acquiring an additional 380,319 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Celldex Therapeutics by 51.0% in the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company's stock worth $71,725,000 after acquiring an additional 654,194 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company's stock worth $50,995,000 after acquiring an additional 479,068 shares during the last quarter.
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
